Skip to main content
Sunshine Lake Pharma Co., Ltd. logo

Sunshine Lake Pharma Co., Ltd. — Investor Relations & Filings

Ticker · 6887 ISIN · CNE1000070M8 HKEX Manufacturing
Open in API
Filings indexed 85 across all filing types
Latest filing 2025-12-29 M&A Activity
Country HK Hong Kong
Listing HKEX 6887

About Sunshine Lake Pharma Co., Ltd.

https://www.hecpharm.com

Sunshine Lake Pharma Co., Ltd. is a research-based, vertically integrated pharmaceutical company engaged in the R&D, production, and commercialization of innovative pharmaceutical products. Its core therapeutic focus areas include infectious diseases, chronic diseases, and oncology, with pipeline assets also targeting conditions such as psoriasis and rheumatoid arthritis. The company emphasizes the globalization and accelerated commercialization of its innovative drug portfolio. To enhance its R&D capabilities, Sunshine Lake Pharma utilizes advanced technology platforms, notably through strategic investments in joint ventures focused on AI and robotics for drug discovery. It also participates in the sourcing and supply of pharmaceutical and animal health ingredients.

Recent filings

Filing Released Lang Actions
INSIDE INFORMATION EQUITY TRANSFERS BETWEEN MEMBERS OF THE GROUP OF CONTROLLING SHAREHOLDERS
M&A Activity Classification · 95% confidence The document is an announcement regarding equity transfers between controlling shareholders of Sunshine Lake Pharma Co., Ltd. It explicitly discusses the implications under the 'Code on Takeovers and Mergers' and the granting of a waiver for a mandatory general offer. While it involves shareholding changes, it is primarily an announcement of a corporate transaction/takeover-related event rather than a simple share issue or director dealing. Given the specific focus on M&A/Takeover Code implications, it fits best under the M&A Activity category.
2025-12-29 English
ARTICLES OF ASSOCIATION
Governance Information Classification · 95% confidence The document is the 'Articles of Association' for Sunshine Lake Pharma Co., Ltd. This document outlines the company's internal governance structure, share classes, board responsibilities, and operational rules. In the context of corporate filings, the Articles of Association are a fundamental governance document that defines the company's legal framework. Among the provided categories, 'Governance Information' (CGR) is the most accurate classification for documents detailing internal rules, board structure, and governance practices.
2025-12-16 English
POLL RESULTS OF THE 2025 SECOND EXTRAORDINARY GENERAL MEETING
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'POLL RESULTS OF THE 2025 SECOND EXTRAORDINARY GENERAL MEETING' and details the voting outcomes for specific resolutions presented at a shareholder meeting. It includes the number of shares voted, the percentage of votes for/against/abstain, and confirms the resolutions were passed. This aligns perfectly with the definition for Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-12-16 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2025
Regulatory Filings Classification · 95% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies to report monthly movements in their securities, share capital, and treasury shares. Since it is a recurring regulatory filing regarding share capital and securities movements that does not fit into specific categories like 'Share Issue' (which usually implies a specific event) or 'Transaction in Own Shares' (which is for buybacks), it is best classified as a general Regulatory Filing (RNS).
2025-12-02 English
FORM OF PROXY FOR THE 2025 SECOND EXTRAORDINARY GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 100% confidence The document is explicitly titled 'FORM OF PROXY FOR THE 2025 SECOND EXTRAORDINARY GENERAL MEETING'. It provides instructions for shareholders to appoint a proxy to vote on their behalf at an upcoming meeting, including specific resolutions to be voted upon. This aligns perfectly with the definition of a Proxy Solicitation & Information Statement (PSI).
2025-11-28 English
NOTICE OF THE 2025 SECOND EXTRAORDINARY GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of the 2025 Second Extraordinary General Meeting' for Sunshine Lake Pharma Co., Ltd. It outlines the agenda, including special resolutions regarding share repurchases and amendments to the Articles of Association, and provides instructions for shareholders to attend and vote. This document is a formal solicitation of proxy and information for an upcoming shareholder meeting, which falls under the Proxy Solicitation & Information Statement category.
2025-11-28 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.